Tenaya Therapeutics, Inc. · NASDAQ:TNYA
Tenaya Therapeutics — Technical Presentation (June 2026)
27 slides from Tenaya Therapeutics's technical presentation, Jun 3, 2026
Slide 1: MyPEAK-1 Interim Data Readout
MyPEAK-1 Interim Data Readout June 3, 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefs and assumptions and on information currently availab
Slide 3: Today's speakers and agenda
Today’s speakers and agenda Today’s Agenda Introductory remarks Faraz Ali MyPEAK-1 objectives Whit Tingley Faraz Ali, MBA Kathy Ivey, Ph.D., Clinical findings Whit Tingley Chief Executive Officer Senior Vice President, Research Biopsy results Kathy Ivey Safety findings Whit Tingley Closing remarks F
Slide 4: MYBPC3-associated HCM is estimated to affect 120,000 people in the U.S. alone
MYBPC3-associated HCM is estimated to affect 120,000 people in the U.S. alone1 A severe and progressive autosomal dominant condition affecting adults, teens, children and infants HCM HEART ~57% of identified genetic variants underlying familial HCM are MYBPC3 mutations2 Thickened left ventricle • Si
Slide 5: TN-201 is the first gene therapy being developed for MYBPC3-associated HCM
TN-201 is the first gene therapy being developed for MYBPC3-associated HCM1 MYBPC3 Pathophysiology TN-201 Mechanism of Action TN-201 cassette AAV9 capsid Heterozygous mutations in the MYBPC3 TN-201 delivers a full-length, Expression of the MYBPC3 gene increases gene lead to significantly lower level
Slide 6: Interim MyPEAK-1 Cohort 1 & 2 Data highlights
HIGHLIGHTS Interim MyPEAK-1 Cohort 1 & 2 Data 1 CLINICAL: Multiple parameters of disease improving; All evaluable patients show signs of cardiac remodeling plus improvements in symptoms 2 BIOPSY: TN-201 is reaching heart cells and being expressed 3 SAFETY: TN-201 well tolerated at both doses 6
Slide 7: MyPEAK-1 Readout: Trial objectives and clinical findings
MyPEAK-1 Readout Trial objectives and clinical findings
Slide 8: MyPEAK-1 Phase 1b/2 clinical trial design
MyPEAK-1 Phase 1b/2 clinical trial design Seeking directional consistency across multiple parameters over time with the goal of halting or even reversing disease progression Study Objectives Design • Safety, tolerability • Open-label, multi-center, dose-escalation and dose-expansion • Dose-finding •
Slide 9: Patients in both cohorts have more severe disease burden vs. average HCM patients
BASELINE CHARACTERISTICS Patients in both cohorts have more severe disease burden vs. average HCM patients June 2026 readout includes 178-104 follow-up for Cohort 1 and 26-52 weeks follow-up for Cohort 2 patients Cohort 1 Cohort 2 Average / % of HCM Patient 1 Patient 2 Patient 3 Patient 4 Patient 5*
Slide 10: Cardiac biomarkers improved or remained stable up to 104 weeks after dosing
BIOMARKER RESULTS Cardiac biomarkers improved or remained stable up to 104 weeks after dosing Cardiac Troponin I Comparison of baseline to MRV Cardiac troponin declined or remained stable within Cohort 1 Cohort 2* the normal/near normal range in five of six patients Patient 1 Patient 2 Patient 3 Pat
Slide 11: Decreases in multiple measures of hypertrophy suggest cardiac remodeling
HYPERTROPHY RESULTS Decreases in multiple measures of hypertrophy suggest cardiac remodeling occurring over time Left Ventricular Mass Index (LVMI) All patients achieved reductions in LVMI Change from baseline to MRV • MyPEAK-1 patients all severely hypertrophied with Cohort 1 Cohort 2* baseline LVM
Slide 12: TN-201 hypertrophy decreases compare favorably with results observed among peers
TN-201 hypertrophy decreases compare favorably with results observed among peers LVMI change from baseline to MRV*1-5 LVPWT change from baseline to MRV*1-5 IVS change from baseline to MRV*1-5 TN-201 TN-201 Mavacamten CAMZYOS (oHCM) CAMZYOS (nHCM) Aficamten Aficamten TN-201 TN-201 Mavacamten CAMZYOS
Slide 13: Symptom burden reduced in all patients by at least one measure
DISEASE BURDEN Symptom burden reduced in all patients by at least one measure following TN-201 treatment New York Heart Assoc. Classification Kansas City Cardiomyopathy Questionnaire Baseline Most recent visit Change from baseline to MRV Cohort 1 Cohort 2* Class I Patient 1 Patient 2 Patient 3 Patie
Slide 14: Functional improvements observed in at least one measure for a majority of Cohort 2 patients
FUNCTIONAL CAPACITY Functional improvements observed in at least one measure for a majority of Cohort 2 patients Six-minute Walk Test Cardiopulmonary Exercise Capacity Cohort 2* change in 6MWD from baseline to MRV Cohort 2* change in pVO2 from baseline to MRV Baseline MRV Difference Baseline MRV Dif
Slide 15: MyPEAK-1 Readout: TN-201 heart biopsy findings
MyPeak-1 Readout TN-201 heart biopsy findings
Slide 16: RNA and protein levels suggest TN-201 expression increases with dose and over time
TN-201 EXPRESSION RNA and protein levels across cohorts suggest TN-201 expression increases with dose and over time Change in TN-201 Expression Over Time TN-201 mRNA Patient 1 Patient 2 Patient 3 Patient 4 Patient 6 Patient 7 • RNA measures are specific for TN-201 Week 8 Week 52 Week 8 Week 52 Basel
Slide 17: MyPEAK-1 Readout: Safety and immunosuppression
MyPEAK-1 Readout Safety and immunosuppression
Slide 18: TN-201 has been well tolerated at both doses with no new treatment-related safety events
SAFETY OBSERVATIONS TN-201 has been well tolerated at both doses with no new treatment-related safety events to report • Adverse events (AEs) associated The most common AE related to TN-201 were reversible, with TN-201 treatment were mild, asymptomatic liver enzyme elevations transient and/or revers
Slide 19: Immunosuppression regimen successfully managed immune response at both doses
SAFETY OBSERVATIONS Immunosuppression regimen successfully managed immune response at both doses Duration & Mean Daily Corticosteroid Dose IS Adjustments During Cohort 1 Mean Daily Dose (mg/day) • Reduced maximum starting dose of Patient 1 27.3 prednisone dose from 80mg to 60mg (3E13 vg/kg) 53.4 Coh
Slide 20: Conclusions and future directions
Conclusions and future directions
Slide 21: Multiple parameters improving with durable responses in Cohort 1 and signals of deeper/faster responses in Cohort 2
CONCLUSIONS Multiple parameters improving with durable responses in Cohort 1 and signals of deeper/faster responses in Cohort 2 MRV Biomarkers Hypertrophy Feel Function Change from (week) baseline to MRV cTnI BNP LVMI LVPWT IVS NYHA KCCQ 6MWD pVO2 Improved Patient 1 104 Stable Cohort 1 Patient 2 104
Slide 22: Opportunity to explore TN-201 in the full spectrum of MYBPC3-associated HCM patients
DEVELOPMENT OPPORTUNITY Opportunity to explore TN-201 in the full spectrum patients with MYBPC3-associated HCM mutations Adults Adolescents Peds Infants Heterozygotes Homozygotes Non-Obstructive Phenotype Obstructive Phenotype (70%) (30%) MyPEAK-1 started in nHCM patients Pediatric MYBPC3-associated
Slide 23: Recent engagements with regulators globally reflect potential future directions
Recent engagements with regulators globally reflect potential future directions Tenaya is engaging with regulators to pursue alignment on pivotal endpoints with an initial focus on the pediatric population where there is significant need PRIME designation received Rare Disease Evidence Principles •
Slide 24: Children with MYBPC3+ disease are at heightened risk for heart failure, arrhythmias, hospitalizations and death
MyCLIMB FINDINGS Children with MYBPC3+ disease are at heightened risk for heart failure, arrhythmias, hospitalizations and death(1) The unmet need in pediatric patients Genotype status impacts outcomes(1) ~3000 diagnosed patients currently under age 18 in the U.S. (2) >90% of patients in MyClimb hav
Slide 25: 2026 anticipated program milestones
2026 anticipated program milestones TN-201 for MYBPC3-associated HCM • Enroll 6E13 vg/kg expansion cohort 1H • MyPEAK-1 interim Cohort 2 data • MyPEAK-1 ~2-year Cohort 1 and ~52-week Cohort 2 data 2H • Continue MyPEAK-1 enrollment • Pursue regulatory alignment on pivotal plans TN-401 for PKP2-associ
Slide 26: Acknowledgements
ACKNOWLEDGEMENTS We extend our deepest gratitude to the dedicated clinical and research staff at all participating institutions and to the participants who volunteered their time, health information, and trust in support of advancing this research. 26
Slide 27: Thank you
Thank you o dts, TENAYA THERAPEUTICS
Tenaya Therapeutics — Technical Presentation (June 2026) on 6ix